SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 9.1% Stake in Royalty Pharma PLC

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming their beneficial ownership of 9.1% of Royalty Pharma PLC's Class A Common Stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 39,245,593.06 shares of Royalty Pharma PLC's Class A Common Stock.
• This ownership represents 9.1% of the total outstanding Class A Common Stock.
• FMR LLC holds sole voting power over 31,680,675.06 shares.
• Both FMR LLC and Abigail P. Johnson hold sole dispositive power over 39,245,593.06 shares.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to a previously reported beneficial ownership.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, with the Johnson family holding predominant ownership of FMR LLC's voting common shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing disclosing beneficial ownership. The continued significant stake by a major institutional investor like FMR LLC can be viewed as a moderately positive signal of confidence in the company, hence a slightly positive score.

Positives

• The continued significant beneficial ownership by a major institutional investor like FMR LLC and its principal, Abigail P. Johnson, signals ongoing confidence in Royalty Pharma PLC.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Risks

• The document does not detail specific risks related to Royalty Pharma PLC's operations or financial performance, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Royalty Pharma PLC's future performance or strategic outlook. It solely reports beneficial ownership.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by FMR LLC and Abigail P. Johnson)

Industry Context

This filing is a routine disclosure by a major asset manager, FMR LLC (Fidelity), indicating its continued significant investment in Royalty Pharma PLC. Such institutional holdings are common in the pharmaceutical and biotechnology royalty acquisition sector, reflecting investor interest in companies with stable, long-term revenue streams from intellectual property.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Investors: Offers insight into the ownership structure and the confidence of large institutional players in Royalty Pharma PLC.

Key Dates

Keywords

Royalty Pharma PLC, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Class A Common Stock, Institutional Investor, SEC Filing, Shareholding, Investment Management